Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.

Lin Zhu et al.PubMed ↗Full text ↗Publisher ↗

A secondary analysis of NCT00000620. The trial’s primary report, PMID 20228404, speaks for it on the map; the numbers here are shown and do not vote.

What the trial testedas reported · 5,518 people · 2020

Not counted

Reduced deaths

−35%−55% to −6%

Bigger than 8 in 10 for all-cause mortality

As reported

HR 0.65, 95% CI 0.45–0.94 · the paper's word: All-cause mortality

One number in the abstract

the abstract, start to end

… on all-cause mortality (adjusted HR = 0.65, 95% CI 0.45-0.94; P = 0.02).

← favours treatmentfavours comparator →

could be chance

All-cause mortality

HR 0.650.45–0.94

StatinsOther lipid agentsAll-cause mortality

1 / 3

23 papers cite it

2020

2021

2022

2023

2024

2025

2026

this paperpooled itcites it

The trial

NCT00000620phase 310,251 enrolled1999a later paper about it